C
Cheng Chen
Researcher at Shanghai University
Publications - 5
Citations - 176
Cheng Chen is an academic researcher from Shanghai University. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Fatty liver. The author has an hindex of 4, co-authored 5 publications receiving 113 citations.
Papers
More filters
Journal ArticleDOI
Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease
TL;DR: The objectives of this paper are to review and discuss the currently known targets, signaling pathways and roles of EGCG that interfere with NAFLD pathogenesis, then providing additional experimental evidence and the foundation for the further studies and clinical applications of E GCG in the prevention and treatment ofNAFLD.
Journal ArticleDOI
Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD).
TL;DR: A review of the potential role of genistein (GE) in the treatment and prevention of NAFLD and some of the currently known targets and signalling pathways of GE inNAFLD are summarized.
Journal ArticleDOI
Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease
Qin Feng,Wensheng Liu,Susan S. Baker,Susan S. Baker,Hongshan Li,Cheng Chen,Qian Liu,Shijie Tang,Lingyu Guan,Maria Tsompana,Rafal Kozielski,Robert D. Baker,Robert D. Baker,Jinghua Peng,Ping Liu,Ruixin Zhu,Yi-Yang Hu,Lixin Zhu,Lixin Zhu,Lixin Zhu +19 more
TL;DR: This study suggests that QHD simultaneously enhanced the hepatic anti-oxidative mechanism, decreased hepatic lipid synthesis, and promoted the regulatory T cell inducing microbiota in the gut.
Journal ArticleDOI
High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis
TL;DR: Basing on the transcriptome microarray assays, the experimental NASH involving liver fibrosis potentially related to dramatically changed ECM-receptor interaction, Toll-like receptor signaling and other signaling pathways.
Journal ArticleDOI
Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1.
TL;DR: In this article, the geniposide and chlorogenic acid combination (namely the GC combination), two active chemical components combined with a unique ratio (67.16:1), presents beneficial effects on high-fat diet-induced NAFLD rodent models.